Clear Search sequence regions


  • cholesterol hdl (2)
  • cholesterol ldl (2)
  • DHCR24 (1)
  • DIO1 (4)
  • HDL (2)
  • Hep (1)
  • humans (1)
  • LDLRAD1 (1)
  • lipid (2)
  • liver (1)
  • liver disease (9)
  • patients (1)
  • rs11206226 (1)
  • rs2294510 (1)
  • target genes (1)
  • TMEM59 (1)
  • Sizes of these terms reflect their relevance to your search.

    Genome-wide association studies (GWAS) have identified genetic variants linked to fat metabolism and related traits, but rarely pinpoint causative variants. This limitation arises from GWAS not considering functional implications of noncoding variants that can affect transcription factor binding and potentially regulate gene expression. The aim of this study is to investigate a candidate noncoding functional variant within a genetic locus flagged by a GWAS SNP associated with non-alcoholic fatty liver disease (NAFLD), a condition characterized by liver fat accumulation in non-alcohol consumers. CRISPR-Cas9 gene editing in HepG2 cells was used to modify the regulatory element containing the candidate functional variant linked to NAFLD. Global gene expression in mutant cells was assessed through RT-qPCR and targeted transcriptomics. A phenotypic assay measured lipid droplet accumulation in the CRISPR-Cas9 mutants. The candidate functional variant, rs2294510, closely linked to the NAFLD-associated GWAS SNP rs11206226, resided in a regulatory element within the DIO1 gene's promoter region. Altering this element resulted in changes in transcription factor binding sites and differential expression of candidate target genes like DIO1, TMEM59, DHCR24, and LDLRAD1, potentially influencing the NAFLD phenotype. Mutant HepG2 cells exhibited increased lipid accumulation, a hallmark of NAFLD, along with reduced LDL-C, HDL-C and elevated triglycerides. This comprehensive approach, that combines genome editing, transcriptomics, and phenotypic assays identified the DIO1 promoter region as a potential enhancer. Its activity could regulate multiple genes involved in the NAFLD phenotype or contribute to defining a polygenic risk score for enhanced risk assessment in NAFLD patients. © 2024. The Author(s).

    Citation

    Casimiro Castillejo-López, José Ramón Bárcenas-Walls, Marco Cavalli, Anders Larsson, Claes Wadelius. A regulatory element associated to NAFLD in the promoter of DIO1 controls LDL-C, HDL-C and triglycerides in hepatic cells. Lipids in health and disease. 2024 Feb 16;23(1):48

    Expand section icon Mesh Tags

    Expand section icon Substances


    PMID: 38365720

    View Full Text